Jason Industries, Inc. (NASDAQ:JASN)
Jason Industries, Inc. (NASDAQ:JASN) represented a move of 0 percent or $0.06 per share and closed its previous day trading session at $1.85. 0 Shares were traded in the last trading session with an Average Volume of 147.8 Million Shares. The stock currently has a Market Capitalization of 53.35 Million.
Jason Industries, Inc. engages in the manufacturing of Finishing, Seating, Components, and Automotive Acoustics. It produces finishing products, including industrial brushes, buffing wheels, and buffing compounds; supplies seating solutions to equipment manufacturers in the motorcycle, lawn and turf care, industrial, agricultural, construction, and power sports end markets, as well as original equipment manufacturer seating for the heavyweight motorcycles; manufactures engineered non-woven, fiber-based acoustical products; manufactures stamped, formed, expanded, and perforated metal components and subassemblies. Jason Industries, Inc. is headquartered in Milwaukee, Wisconsin.
The stock traded between $1.75 and $3.88 over 1-Year time period showing its price to sales ratio of 0.09. Jason Industries, Inc. (NASDAQ:JASN) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-29.65 and 200-Day Simple Moving Average of $-32.65. Its Price to Free Cash Flow is 2.08 and Price to Book of 0.
Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Jason Industries, Inc. (NASDAQ:JASN) reported its Actual EPS of $-0.12/share. The analysts offering Earnings Estimates for the company were believing that Jason Industries, Inc. could bring EPS of $-0.05/share. The difference between Actual EPS and Estimated EPS was -0.07 Percent. Thus showing an Earnings Surprise of -140 Percent.
Soligenix, Inc. (NASDAQ:SNGX)
In the last trading session, Soligenix, Inc. (NASDAQ:SNGX) added its value by 0% closing at the price of $1. The stock currently has market capitalization of 18.07 Million, with average volume of 213.25 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Soligenix, Inc. (NASDAQ:SNGX) is showing beta of 0.84. This particular value of beta suggests that Soligenix, Inc. (NASDAQ:SNGX) has historically moved 84% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Soligenix, Inc. (NASDAQ:SNGX) is at $-0.83.
The stock currently has RSI of 31.19. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec (r) (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Soligenix, Inc. (NASDAQ:SNGX) topped its 52-week high price of $3.70 on 03/22/18 and 52-Week Low Price of $0.91 on 06/28/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 6.74% and monthly volatility of 7.13% respectively.